HIMS vs. REGN
HIMS (Hims & Hers Health, Inc.) and REGN (Regeneron Pharmaceuticals, Inc.) are both stocks. HIMS operates in Household & Personal Products (Consumer Defensive), while REGN operates in Biotechnology (Healthcare). Over the past 5 years, HIMS returned 15.10%/yr vs 3.39%/yr for REGN. At a 0.12 correlation, their price movements are largely independent.
Performance
HIMS vs. REGN - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, HIMS achieves a -16.32% return, which is significantly higher than REGN's -20.58% return.
HIMS
- 1D
- 3.74%
- 1M
- -3.89%
- YTD
- -16.32%
- 6M
- -30.55%
- 1Y
- -51.77%
- 3Y*
- 44.53%
- 5Y*
- 15.10%
- 10Y*
- —
REGN
- 1D
- -3.79%
- 1M
- -14.36%
- YTD
- -20.58%
- 6M
- -12.84%
- 1Y
- 24.63%
- 3Y*
- -6.19%
- 5Y*
- 3.39%
- 10Y*
- 5.18%
HIMS vs. REGN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
HIMS Hims & Hers Health, Inc. | -16.32% | 34.28% | 171.69% | 38.85% | -2.14% | -55.14% | 47.47% | 1.02% |
REGN Regeneron Pharmaceuticals, Inc. | -20.58% | 8.96% | -18.90% | 21.73% | 14.25% | 30.72% | 28.66% | 33.33% |
Correlation
The correlation between HIMS and REGN is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.06 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.12 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.15 |
Correlation (All Time) Calculated using the full available price history since Sep 16, 2019 | 0.12 |
Fundamentals
HIMS:
$6.20B
REGN:
$65.84B
HIMS:
-$0.05
REGN:
$41.05
HIMS:
2.81
REGN:
4.42
HIMS:
13.91
REGN:
2.10
HIMS:
$2.37B
REGN:
$14.92B
HIMS:
$1.70B
REGN:
$12.61B
HIMS:
$16.04M
REGN:
$5.74B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
HIMS vs. REGN — Risk / Return Rank
HIMS
REGN
HIMS vs. REGN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Hims & Hers Health, Inc. (HIMS) and Regeneron Pharmaceuticals, Inc. (REGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| HIMS | REGN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.29 | ||
| Sortino ratioReturn per unit of downside risk | -1.67 | ||
| Omega ratioGain probability vs. loss probability | 0.95 | 1.16 | -0.21 |
| Calmar ratioReturn relative to maximum drawdown | -0.67 | 0.96 | -1.62 |
| Martin ratioReturn relative to average drawdown | -1.09 | 3.20 | -4.29 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| HIMS | REGN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.54 | 0.75 | -1.29 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.18 | 0.11 | +0.07 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.16 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.21 | 0.16 | +0.05 |
Drawdowns
HIMS vs. REGN - Drawdown Comparison
The maximum HIMS drawdown since its inception was -87.29%, roughly equal to the maximum REGN drawdown of -91.81%. Use the drawdown chart below to compare losses from any high point for HIMS and REGN.
Loading charts...
Drawdown Indicators
| HIMS | REGN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -87.29% | -91.81% | +4.52% |
Max Drawdown (1Y)Largest decline over 1 year | -78.06% | -25.85% | -52.21% |
Max Drawdown (3Y)Largest decline over 3 years | -78.88% | -59.69% | -19.19% |
Max Drawdown (5Y)Largest decline over 5 years | -78.88% | -59.69% | -19.19% |
Max Drawdown (10Y)Largest decline over 10 years | — | -59.69% | — |
Current DrawdownCurrent decline from peak | -60.47% | -48.71% | -11.76% |
Average DrawdownAverage peak-to-trough decline | -43.22% | -42.39% | -0.83% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 47.51% | 7.73% | +39.78% |
Volatility
HIMS vs. REGN - Volatility Comparison
Hims & Hers Health, Inc. (HIMS) has a higher volatility of 26.28% compared to Regeneron Pharmaceuticals, Inc. (REGN) at 12.61%. This indicates that HIMS's price experiences larger fluctuations and is considered to be riskier than REGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| HIMS | REGN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 26.28% | 12.61% | +13.67% |
Volatility (6M)Calculated over the trailing 6-month period | 66.46% | 22.61% | +43.85% |
Volatility (1Y)Calculated over the trailing 1-year period | 96.13% | 33.09% | +63.04% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 83.39% | 30.82% | +52.57% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 77.19% | 32.18% | +45.01% |
Dividends
HIMS vs. REGN - Dividend Comparison
HIMS has not paid dividends to shareholders, while REGN's dividend yield for the trailing twelve months is around 0.60%.
| Position | TTM | 2025 |
|---|---|---|
HIMS Hims & Hers Health, Inc. | 0.00% | 0.00% |
REGN Regeneron Pharmaceuticals, Inc. | 0.60% | 0.46% |
Financials
HIMS vs. REGN - Financials Comparison
This section allows you to compare key financial metrics between Hims & Hers Health, Inc. and Regeneron Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HIMS vs. REGN - Profitability Comparison
HIMS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported a gross profit of 396.79M and revenue of 608.10M. Therefore, the gross margin over that period was 65.3%.
REGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.94B and revenue of 3.61B. Therefore, the gross margin over that period was 81.4%.
HIMS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported an operating income of -78.32M and revenue of 608.10M, resulting in an operating margin of -12.9%.
REGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported an operating income of 642.90M and revenue of 3.61B, resulting in an operating margin of 17.8%.
HIMS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Hims & Hers Health, Inc. reported a net income of -92.12M and revenue of 608.10M, resulting in a net margin of -15.2%.
REGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a net income of 727.20M and revenue of 3.61B, resulting in a net margin of 20.2%.
Frequently Asked Questions
HIMS and REGN have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
HIMS has higher volatility (26.28%) compared to REGN (12.61%). In terms of maximum drawdown, HIMS dropped -87.29% vs REGN's -91.81%.
REGN currently has the higher Sharpe Ratio (0.75 vs -0.54), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for HIMS and REGN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer